Live News EQUITY L impact Jul 16, 2026, 12:26 PM UTC

ATYR Reiterate Overweight and $7 PT as EFZO-FIT Posthoc Analysis Further Supports Ph3 Restrictive Patient Selection @ Piper

ATYR Reiterate Overweight and $7 PT as EFZO-FIT Posthoc Analysis Further Supports Ph3 Restrictive Patient Selection @ Piper

SquawkNews Newsroom

ATYR Reiterate Overweight and $7 PT as EFZO-FIT Posthoc Analysis Further Supports Ph3 Restrictive Patient Selection @ Piper